+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 826 Actively Recruiting clinical trials

P

Actively Recruiting

Diffuse gliomas are aggressive tumors affecting the brain and spinal cord, especially in people with IDH1 or IDH2 gene mutations. Researchers are evaluating the study drug zotiraciclib in people aged 15 and older with recurrent diffuse gliomas who have these specific mutations. The trial aims to find out if zotiraciclib is effective and safe for this group, focusing on progression-free survival and the best dose to use. Participants will take zotiraciclib capsules by mouth on days 1, 4, 8, 11, 15, and 18 of each 28-day cycle, for up to 18 cycles about 1.5 years. Those in the surgical group will receive an additional dose before surgery or biopsy, followed by treatment after recovery. Dose levels may change based on tolerance, and participants may also receive medications to prevent side effects. During the study, participants will visit the clinic about once a month for physical exams, blood and urine tests, and heart function assessments. Brain MRIs will be done every 8 weeks. Participants will track their medication use in a diary. Researchers will monitor safety, treatment effects, and disease progression throughout the trial and follow-up period.

Age: 15Years - 99YearsAll GendersPhase 1Phase 2
2 locations
E

Actively Recruiting

Researchers are studying how an imaging agent called 18F-DCFPyL can detect how well patients with localized prostate cancer respond to standard treatments like stereotactic body radiation therapy SBRT with or without androgen deprivation therapy ADT. The purpose is to see if this imaging method can identify disease persistence or recurrence earlier than current methods, which could allow for more effective treatments. This research focuses on men 18 years and older with newly diagnosed prostate cancer without distant metastases. Participants will receive SBRT with or without ADT as their treatment. Imaging with 18F-DCFPyL PETCT scans and multiparametric MRI mpMRI will be done at baseline, 8 weeks after starting ADT if applicable, 6 months after completing SBRT, and at any recurrence. The imaging involves an IV injection of the tracer and scans lasting 45 minutes to 1 hour. The study includes cohorts receiving different combinations of radiation and ADT to assess imaging response. During the study, participants will undergo medical history reviews, physical exams, blood and urine tests, and complete quality of life questionnaires. Follow-up visits will occur 1 month after treatment, then every 3 months for a year, and every 6 months for another year to monitor outcomes. Researchers will measure imaging response over time and track biochemical control and quality of life for up to 2 years after treatment completion.

Age: 18Years - 120YearsMALEPhase 2
1 location
E

Actively Recruiting

This research evaluates the use of a new PET imaging tracer called 18FFAPI-74 for detecting certain types of cancer, including pancreatic ductal adenocarcinoma, cholangiocarcinoma, hepatocellular carcinoma, gastric, bladder, ovarian cancers, pheochromocytomaparaganglioma, small cell lung cancer, extrapulmonary neuroendocrine cancer, mesothelioma, and sarcoma. The study compares the effectiveness of 18FFAPI-74 PET scans to the currently approved imaging methods, such as 18F-FDG PET scans and other standard imaging like CT or MRI, to see if the new tracer can better visualize tumors. Participants receive two baseline PET scans one with the 18FFAPI-74 tracer injected intravenously, followed by imaging about an hour later, and a second scan with the approved 18F-FDG tracer within one week. If the 18FFAPI-74 scan shows tumors, additional scans with this tracer will be done during future routine treatment scans. When the 18F-FDG scan also shows tumors, it will be repeated alongside the 18FFAPI-74 scan. Scans will not be repeated if the 18FFAPI-74 scan does not detect tumors. Scans may be repeated if cancer progresses within two years. During the study, participants will be followed for two years with regular follow-up calls and possible additional PET scans if cancer recurrence or progression is suspected. Researchers will assess the number of lesions detected by scans, tracer uptake levels, and the safety of the 18FFAPI-74 PET imaging procedure. The study aims to improve cancer detection methods and monitor disease progression over time.

Age: 18Years - 120YearsAll GendersPhase 2
1 location
E

Actively Recruiting

Researchers are evaluating the use of the radiotracer 18F-fluciclovine in imaging scans to detect multiple myeloma MM, a type of blood cancer that is currently incurable and often returns after treatment. The study aims to see if 18F-fluciclovine PETCT scans can better identify returning disease compared to the standard 18F-FDG PETCT scans. This is a phase 2, open-label trial involving adults with newly diagnosed or relapsed multiple myeloma. Participants will receive intravenous injections of 18F-fluciclovine and undergo PETCT scans at three different time points initially, after treatment completion or six months later depending on disease status, and then at disease progression or after five years. Each visit includes two PETCT scansone with 18F-fluciclovine and one with 18F-FDGplus optional MRI scans and bone marrow biopsies. The study compares the imaging results to assess which radiotracer better detects disease. Throughout the study, participants will have blood tests, imaging scans, and bone marrow biopsies to monitor disease status. Researchers will evaluate how well 18F-fluciclovine measures disease volume, identifies minimal residual disease, and tracks response to treatment. Safety of the radiotracer will also be assessed. Participants will be followed up to five years, with visits spaced according to their treatment and disease progression.

Age: 18Years - 120YearsAll GendersPhase 2
1 location
P

Actively Recruiting

Researchers are studying the drug Aza-TdC, which targets advanced solid tumors that have worsened after standard treatments or have no effective therapies. This drug aims to reactivate genes that slow tumor growth by inhibiting DNA methylation, a process that silences tumor suppressor genes. The study is a Phase 1 trial focusing on the safety and dosage of Aza-TdC in patients with advanced cancers. Participants will take Aza-TdC orally in 21-day cycles. Each cycle includes taking the drug once daily for 5 days per week over 2 weeks, followed by one week without the drug. The first cycle includes repeated screening tests, and subsequent cycles involve blood and pregnancy tests, along with tumor scans every 6 weeks. Treatment continues as long as the drug is tolerated and the cancer remains stable or improves. Throughout the study, participants undergo medical history reviews, blood and urine tests, heart activity monitoring, and tumor scans. Researchers measure safety, drug levels in the body, gene reactivation in tumor cells, and changes in tumor DNA. The study also monitors how the drug affects DNA damage response and gene expression in tumor tissue. Participants may remain in the study until disease progression or unacceptable side effects occur.

Age: 18Years - 120YearsAll GendersPhase 1
1 location
I

Actively Recruiting

Healthy Volunteer

This research aims to determine whether the enzyme phosphodiesterase 4B PDE4B is reduced in the brains of individuals experiencing a major depressive episode MDE as part of major depressive disorder MDD. The study also evaluates the optimal length for PET brain scans using the tracer 18FPF-06445974, the reliability of these scans, and how PDE4B binding relates to clinical rating scales. Additionally, it investigates if PDE4B binding can be blocked by the drug apremilast. Participants will undergo several assessments including brain magnetic resonance imaging MRI and positron emission tomography PET scans using the radioactive tracer 18FPF-06445974 injected intravenously. Some participants may receive oral apremilast and have lung scans following brain scans. The PET scan lasts up to 4 hours with a break, and blood pressure, heart rate, breathing, and blood samples will be monitored during the procedure. Participants will attend up to five clinic visits involving physical exams, blood tests, heart function assessments, psychiatric evaluations, and questionnaires about mental health. Researchers will measure PDE4B distribution volume in the brain and explore correlations with clinical symptoms. Safety measures include monitoring vital signs during scans, and some participants may have repeat scans. Total participation duration and detailed assessments occur over approximately three years.

Age: 18Years - 70YearsAll GendersPhase 1
1 location
E

Actively Recruiting

Researchers are studying tumors that have high levels of somatostatin receptors SSTRs on their surface. These tumors include those found in the lung, head and neck, digestive tract, kidneys, and near the adrenal glands. The study aims to evaluate a drug called 212PbVMT-Alpha-NET, which targets these receptors, to see if it can help shrink tumors that have spread and cannot be removed by surgery. Participants will receive 212PbVMT-Alpha-NET intravenously on the first day of each of four 8-week treatment cycles. Some participants will also receive a related imaging drug, 203PbVMT-Alpha-NET, before each treatment to track how the drug spreads in the body through scans. Participants stay in the hospital for a few nights after each treatment and have weekly blood tests during each cycle. Imaging scans using 68Ga-DOTATATE PETCT will also be done periodically to monitor the disease. During the study, participants will undergo physical exams, blood and urine tests, heart function tests, and may provide tumor tissue samples. Safety and effectiveness will be evaluated through regular lab tests, imaging, and sample collections. After treatment ends, participants will return for follow-up visits every 12 weeks for the first 3 years, then every 6 months for years 4 to 6, or until the disease progresses. Beyond 6 years, yearly health assessments will continue for up to 10 years after the last treatment visit.

Age: 18Years - 120YearsAll GendersPhase 1
1 location
B

Actively Recruiting

Researchers are collecting data and biological samples from people aged 3 to 100 years with allergic or sinus diseases such as pollen allergies, asthma, eczema, and other atopic conditions. This observational study aims to create a biorepository to better understand and support research on prevention and treatment of these diseases. The study is conducted at a single site with possible telehealth visits and sample submissions. Participants will undergo clinical evaluations including blood draws, nasal cell and fluid collections, skin swabs, urine samples, allergy skin prick tests, and lung function tests. Additional tissue samples may be collected during routine clinical procedures like nasal polyp removal or biopsies. The study involves baseline, annual, and end-of-study visits over 1 to 3 years, with data collection continuing during this time. Participants will complete online questionnaires about their symptoms and health, and researchers will monitor clinical, laboratory, and diagnostic data. Samples and data are stored for future medical research. Throughout the study, standard care treatments will be managed by participants primary physicians or specialists. The main outcome is to establish a repository of clinical information and specimens from individuals with allergic and atopic diseases over 20 years.

Age: 3Years - 100YearsAll Genders
1 location
C

Actively Recruiting

Healthy Volunteer

Researchers are studying patients who have been infected with the Lyme bacteria, Borrelia burgdorferi, to find out if the bacteria remain alive inside the body after antibiotic treatment and whether they cause ongoing symptoms. The study seeks to better understand post-treatment Lyme disease syndrome PTLDS and aims to develop clear diagnostic criteria and future treatment plans. The study includes several groups such as chronic Lyme disease patients, Lyme arthritis patients, seropositive controls without symptoms, recovered patients, multiple sclerosis patients, and healthy volunteers. Participants will undergo various tests including blood tests for genetic immune markers, leukapheresis to collect white blood cells or blood draws, lumbar punctures to collect spinal fluid, brain MRI scans, neuropsychologic testing, and possibly hearing tests and urine collection. Those with positive Borrelia results will be followed every 3 to 6 months to confirm infection and may be treated with the antibiotic ceftriaxone. After treatment, follow-up visits will occur at 1 week, 3 months, 6 months, and 12 months, with repeated tests and imaging as needed. Participants without active infection or in control groups may be reevaluated every 6 to 12 months. During the study, participants undergo physical examinations and various evaluations to track disease progression and immune response. The research team collects detailed information through laboratory tests, imaging, and questionnaires to measure clinical outcomes and biological markers over time. The study offers long-term monitoring to better understand PTLDS and related conditions, with participation duration varying by group and follow-up needs.

Age: 13Years - 99YearsAll Genders
1 location
W

Actively Recruiting

Researchers are evaluating a culturally-tailored home-based physical activity program designed for Hispanic or LatinoLatina adolescent and young adult childhood cancer survivors. These survivors may face long-term effects like weight gain, fatigue, and reduced physical fitness after cancer treatment. The study aims to see if this culturally-relevant program can help increase physical activity and improve overall health compared to using a Fitbit tracker alone. The study has two stages. In Stage 1, 20 Latinx survivors participate in developing the intervention using Fitbit trackers, text messages, social media support, wearable activity devices, and interviews over 9 months. In Stage 2, 170 survivors who do not meet physical activity guidelines are randomized to either the intervention group, which includes Fitbit use, weekly goal-setting, peer support via social media and Zoom meetings, and optional activity partners, or a control group that only uses Fitbit trackers for 12 weeks. The intervention includes an intensive phase with weekly sessions followed by a 4-week maintenance phase. Participants will wear Fitbit trackers daily and engage in goal-setting, peer discussions, and physical activity reminders. Researchers will measure moderate to vigorous physical activity, sedentary time, and health-related quality of life over 12 weeks. Additional evaluations include physiological markers of heart and metabolic health and qualitative interviews to improve the program. The study lasts through the intervention phases with ongoing monitoring and support for participants.

Age: 15Years - 20YearsAll GendersPhase 2
77 locations

1-10 of 826

1